The aim of the study is to evaluate the role of cytoreductive nephrectomy (CN) with thrombectomy before targeted molecular therapy (TMT) on survival in metastatic renal cell carcinoma (mRCC) with venous tumor thrombus.
We performed a retrospective analysis of 47 patients treated in our center from April 2008 to October 2014. In the study, 20 patients underwent CN with thrombectomy followed by targeted therapy (group 1); 15 patients received targeted therapy alone (group 2); and 12 patients underwent CN with thrombectomy alone (group 3). The overall survival (OS) and cancer-specific survival (CSS) were calculated according to the Kaplan-Meier survival curve method, and prognostic variables were assessed by Cox regression analyses.
The median follow-up times of group 1, group 2, and group 3 were 24.5, 12, and 6.5 months, respectively. During follow-up, in both group 1 and group 3, 12 patients died. In group 2, 14 patients died. The median OS of group 1, group 2, and group 3 was 22, 12, and 6 months, respectively (P < 0.001). Compared with surgery alone and targeted therapy alone, patients with cytoreductive surgery before targeted therapy had statistically better survival benefits (P < 0.001, P = 0.009, respectively). On univariate analysis, the number of metastatic sites (P = 0.004) was a statistically significant prognostic factor influencing OS.
Our single-center experience showed that CN with thrombectomy before targeted therapy improved the survival of patients with mRCC with venous tumor thrombus. The number of metastatic sites was an independent prognostic factor influencing OS.
World journal of surgical oncology. 2017 Jan 05*** epublish ***
Nienie Qi, Pengjie Wu, Jinchao Chen, Teng Li, Xianghui Ning, Jin Wang, Kan Gong
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, China., Department of Urology, Beijing Hospital, Beijing, China., Department of cardiac surgery, Peking University First Hospital, Beijing, China., Department of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center, No. 8, Xishiku St., Xicheng Dist, Beijing, 100034, China. .